Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Hamid Ahmadieh, MD
- Phone Number: +98 21 22585952
- Email: hahmadieh@hotmail.com
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of, 16666
- Recruiting
- Hamid Ahmadieh, MD
-
Contact:
- Hamid Ahmadieh, MD
- Phone Number: +98 21 22585952
- Email: hahmadieh@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cases with rhegmatogenous retinal detachment complicated by PVR grade C
Exclusion Criteria:
- History of pars plana vitrectomy for PVR grade C
- History of silicone oil injection
- History of ocular trauma
- Diabetic retinopathy
- Glaucoma
- Giant retinal tear
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: 2
|
|
|
Active Comparator: 1
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Retinal reattachment rate
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
visual acuity
|
|
PVR recurrence,
|
|
macular pucker,
|
|
reoperation,
|
|
ocular hypotony,
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Diseases
- Vitreoretinopathy, Proliferative
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Anticoagulants
- Gout Suppressants
- Dexamethasone
- Heparin
- Colchicine
- Heparin, Low-Molecular-Weight
- Tinzaparin
- Dalteparin
Other Study ID Numbers
Other Study ID Numbers
- 8404 (Other Identifier: FCDGC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.